Final Results of a Phase 2, Open-Label Study of Ramucirumab (IMC-1121B; RAM), an IGG1 MAB Targeting Vegfr-2, with Paclitaxel and Carboplatin as First-Line Therapy in Patients (PTS) with Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) (NCT00735696)
Year: 2012
Type: article
Study design: Clinical Trial
Source: Annals of Oncology
Institutions: University of Colorado Cancer Center, NYU Langone Health, New York University, University of California, San Francisco, Albert Einstein College of Medicine, Montefiore Medical Center, Guy's Hospital, King's College London, Swedish Medical Center, The University of Texas at San Antonio Health Science Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3000022437